Investigating a new therapy for chronic kidney disease using a protein called ANGPTL4
Official title: Recombinant hANGPTL4 and CKD
Funded at Rush University Medical Center · NIH-10993136 · Data updated 2026-11-12
This study is looking at a special protein called ANGPTL4 to see if it can help people with chronic kidney disease by reducing protein in their urine and protecting their kidneys, especially for those who haven't found relief with current treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rush University Medical Center NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project start | December 1, 2023 |
| Project end | November 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $594,447 |
| NIH project number | 5R01DK137919-02 |
| Project ID | NIH-10993136 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with chronic kidney disease, particularly those with diabetic nephropathy or focal segmental glomerulosclerosis.
✕Less likely to help
Patients with acute kidney injury or those whose CKD is not related to diabetes or glomerulosclerosis may not benefit from this research.
What this research studies
This research focuses on the potential of a protein known as Angiopoietin-like 4 (ANGPTL4) to reduce proteinuria and slow the progression of chronic kidney disease (CKD). The study involves testing mutated versions of ANGPTL4 in rat models of diabetic nephropathy and focal segmental glomerulosclerosis to assess their effectiveness in preserving kidney function and reducing kidney damage. By examining how ANGPTL4 interacts with kidney cells, the researchers aim to uncover new therapeutic strategies for patients with CKD who are not responding well to existing treatments.
Why it matters
Potential benefit: If successful, this research could lead to a novel treatment that significantly slows the progression of chronic kidney disease and improves kidney function in affected patients.
How similar studies have gone: Previous studies have shown promising results with similar approaches using ANGPTL4 in animal models, indicating potential for success in human applications.
Where this research is happening
-
Rush University Medical Center
Chicago, United States Active
Researchers
- Principal investigator: Chugh, Sumant Singh — Rush University Medical Center
- Study coordinator: Chugh, Sumant Singh
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.